Promises and challenges of immunogenic chemotherapy in multiple myeloma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109747" target="_blank" >RIV/00843989:_____/22:E0109747 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/61988987:17110/22:A2302J5B
Výsledek na webu
<a href="https://www.mdpi.com/2073-4409/11/16/2519" target="_blank" >https://www.mdpi.com/2073-4409/11/16/2519</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cells11162519" target="_blank" >10.3390/cells11162519</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Promises and challenges of immunogenic chemotherapy in multiple myeloma
Popis výsledku v původním jazyce
Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients. Over the past two decades, remarkable preclinical efforts to understand MM biology have led to the clinical approval of several targeted and immunotherapeutic agents. Among them, it is now clear that chemotherapy can also make cancer cells "visible" to the immune system and thus reactivate anti-tumor immunity. This knowledge represents an important resource in the treatment paradigm of MM, whereas immune dysfunction constitutes a clear obstacle to the cure of the disease. In this review, we highlight the importance of defining the immunological effects of chemotherapy in MM with the goal of enhancing the clinical management of patients. This area of investigation will open new avenues of research to identify novel immunogenic anti-MM agents and inform the optimal integration of chemotherapy with immunotherapy.
Název v anglickém jazyce
Promises and challenges of immunogenic chemotherapy in multiple myeloma
Popis výsledku anglicky
Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients. Over the past two decades, remarkable preclinical efforts to understand MM biology have led to the clinical approval of several targeted and immunotherapeutic agents. Among them, it is now clear that chemotherapy can also make cancer cells "visible" to the immune system and thus reactivate anti-tumor immunity. This knowledge represents an important resource in the treatment paradigm of MM, whereas immune dysfunction constitutes a clear obstacle to the cure of the disease. In this review, we highlight the importance of defining the immunological effects of chemotherapy in MM with the goal of enhancing the clinical management of patients. This area of investigation will open new avenues of research to identify novel immunogenic anti-MM agents and inform the optimal integration of chemotherapy with immunotherapy.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Cells
ISSN
2073-4409
e-ISSN
2073-4409
Svazek periodika
11
Číslo periodika v rámci svazku
article 2519
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
15
Strana od-do
1-15
Kód UT WoS článku
000846956900001
EID výsledku v databázi Scopus
2-s2.0-85136615614